Saidal Algerie SpA in Consumer Health (Algeria)
Public company Saidal Algerie SpA is expected to continue focusing its production activities on prescription drugs and the investment plan which it announced during 2010, set to include seven new and refurbished manufacturing plants, including a large insulin production plant in partnership with Novo Nordisk, which began producing in May 2016 in response to the rising prevalence of diabetes in the country. The investment budget for this project is €160 million and the company is expecting to sec...
Euromonitor International Local Company Profiles are a concise set of briefings detailing the strategic direction taken by a company. Discover key contact details, the company background and their competitive positioning through this collection of snapshot company profiles.
Product coverage: Allergy Care, Herbal/Traditional Products, OTC, Paediatric Consumer Health, Sports Nutrition, Vitamins and Dietary Supplements, Weight Management and Wellbeing.
Data coverage: market sizes (historic and forecasts), company shares, brand shares and distribution data.
Why buy this report?
Learn how to effectively navigate the market research process to help guide your organization on the journey to success.Download eBook